These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15168349)

  • 1. Immune signals in the context of secondary osteoporosis.
    Okada Y; Tanaka Y
    Histol Histopathol; 2004 Jul; 19(3):863-6. PubMed ID: 15168349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary osteoporosis or secondary contributors to bone loss in fracture. The relevance of immune system to bone metabolism].
    Tanaka Y
    Clin Calcium; 2013 Sep; 23(9):1265-70. PubMed ID: 23999361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoblasts and osteoclasts in bone remodeling and inflammation.
    Tanaka Y; Nakayamada S; Okada Y
    Curr Drug Targets Inflamm Allergy; 2005 Jun; 4(3):325-8. PubMed ID: 16101541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inflammatory cytokines for osteoclastogenesis].
    Tanaka Y
    Nihon Rinsho; 2005 Sep; 63(9):1535-40. PubMed ID: 16164208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent progress of pathogenesis and treatments in rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2005 Jul; 15(7):23-8. PubMed ID: 15995292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between osteoblast and osteoclast: impact in bone disease.
    Phan TC; Xu J; Zheng MH
    Histol Histopathol; 2004 Oct; 19(4):1325-44. PubMed ID: 15375775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rheumatism and bone metabolism].
    Dischereit G; Lange U
    Orthopade; 2019 Nov; 48(11):911-916. PubMed ID: 31531702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are nonresorbing osteoclasts sources of bone anabolic activity?
    Karsdal MA; Martin TJ; Bollerslev J; Christiansen C; Henriksen K
    J Bone Miner Res; 2007 Apr; 22(4):487-94. PubMed ID: 17227224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediators of inflammation and bone remodeling in rheumatic disease.
    Shaw AT; Gravallese EM
    Semin Cell Dev Biol; 2016 Jan; 49():2-10. PubMed ID: 26481971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammation and bone metabolism in rheumatoid arthritis. Pathogenetic viewpoints and therapeutic possibilities].
    Oelzner P; Hein G
    Med Klin (Munich); 1997 Oct; 92(10):607-14. PubMed ID: 9446010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function of matrix IGF-1 in coupling bone resorption and formation.
    Crane JL; Cao X
    J Mol Med (Berl); 2014 Feb; 92(2):107-15. PubMed ID: 24068256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The physiopathology of osteoporosis: the role of local factors].
    Girasole G; Giuliani N
    Ann Ital Med Int; 1995 Oct; 10 Suppl():9S-17S. PubMed ID: 8562275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biology of the basic multicellular unit and the pathophysiology of osteoporosis.
    Jilka RL
    Med Pediatr Oncol; 2003 Sep; 41(3):182-5. PubMed ID: 12868116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Cellular mechanism and etiology of osteoporosis].
    Koga T; Takayanagi H
    Clin Calcium; 2015 Sep; 25(9):1293-300. PubMed ID: 26320528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospects of treatment using interferon for bone diseases].
    Iba K; Takada J; Yamashita T
    Nihon Rinsho; 2006 Jul; 64(7):1275-80. PubMed ID: 16838644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.
    Martin TJ; Ng KW
    J Cell Biochem; 1994 Nov; 56(3):357-66. PubMed ID: 7876329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
    Dresner-Pollak R; Rosenblatt M
    J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.